Health Affairs

Editor’s Note: Some of the key differences between the House and Senate health reform bills revolve around drug pricing. For example, the House bill requires drug manufacturers to provide, at a minimum, the same rebates for drugs provided to dual eligibles — those eligible for both Medicare and Medicaid — under Medicare Part D as... Read the rest of this entry »

At last policymakers and readers are being set straight that the prices of drugs are not related to the immense costs of research and development but to “what the market will bear,” as James Robinson put it in his Health Affairs Blog post last fall. Never mind that pharmaceutical executives told Congress and everyone else... Read the rest of this entry »